Probiotic (VSL#3) for Gulf War Illness

reportActive / Technical Report | Accession Number: ADA555241 | Open PDF

Abstract:

The overall objective of the study was to determine whether Bifidobacterium infantis 35624 Align will improve symptoms of GW illness. We have not started the study as yet. This is due to inability to get IND Investigational New Drug number for the probiotic, Bifidobacterium infantis 35624 Align . The manufactures of Bifidobacterium infantis 35624 Align , Procter Gamble could not provide the necessary manufacturing information to Food and Drug Administration FDA. We requested the Department of Defense to allow us to use another commonly used probiotic, VSL3. The Department of Defense contract has been modified to include this change. The Confidentiality Disclosure Agreement between VSL Pharmaceuticals and the Department of Veterans Affairs has been agreed.

Author(s):
Tuteja, Ashok
Author Organization(s):
WESTERN INST FOR BIOMEDICAL RESEARCH SALT LAKE CITY UT
Descriptive Note:
Annual rept. 8 Sep 2010-7 Sep 2011
Supplementary Note:
DOI: 10.21236/ADA555241
Pagination:
0010

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Contract/Grant Number(s):
W81XWH-10-1-0593
Monitor Series:
USAMRMC
 Subject Terms
Joint Capability Areas:
JCA_6_Net Centric; JCA_1.2.5_Lessons Learned; JCA_1.2_Force Preparation; JCA_1_Force Support; JCA_5_Command and Control; JCA_6.1_Information Transport; JCA_1.2.3_Educating; JCA_4.1_Deployment and Distribution; JCA_8_Building Partnerships
Communities of Interest:
No COI(s) Identified
Descriptor(s):
*DIARRHEA, *DRUGS, *ILLNESS, AGREEMENTS, CONTRACTS, MANUFACTURING, SIGNS AND SYMPTOMS
Field(s)/Group(s):
Medicine and Medical Research, Pharmacology
Keyword(s):
*GULF WAR ILLNESS, *IRRITABLE BOWEL SYNDROME, *PROBIOTIC
Report Date:
2011 Oct 01
Creation Date:
2012 Mar 05